Heinrich Haas
Chief Technology Officer NeoVac
Seminars
Thursday 18th February 2027
Engineering Next-Generation LNPs for Precise Tissue Targeting, Repeat Dosing & Enhanced Clinical Performance
1:30 pm
- Leveraging modular lipid architectures to tune biodistribution, pharmacokinetics, and immunogenicity across diverse therapeutic applications
- Enabling cell- and organ-specific delivery through ligandfunctionalised LNP technologies to improve targeting precision and therapeutic index
- Developing LNP platforms suitable for repeat administration while maintaining favourable safety and efficacy profiles in clinical settings
- Demonstrating versatility across mRNA, saRNA, and other nucleic acid payloads to expand the therapeutic potential of LNP-enabled medicines
